Insight Molecular Diagnostics (IMDX) Operating Margin (2020 - 2025)
Historic Operating Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 4249.23%.
- Insight Molecular Diagnostics' Operating Margin rose 75029400.0% to 4249.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 1392.91%, marking a year-over-year increase of 47556100.0%. This contributed to the annual value of 3245.14% for FY2024, which is 15727500.0% down from last year.
- As of Q3 2025, Insight Molecular Diagnostics' Operating Margin stood at 4249.23%, which was up 75029400.0% from 1900.0% recorded in Q2 2025.
- Over the past 5 years, Insight Molecular Diagnostics' Operating Margin peaked at 1969.7% during Q1 2023, and registered a low of 11752.17% during Q3 2024.
- Moreover, its 5-year median value for Operating Margin was 1791.36% (2023), whereas its average is 2575.16%.
- As far as peak fluctuations go, Insight Molecular Diagnostics' Operating Margin surged by 516830700bps in 2021, and later plummeted by -102339900bps in 2024.
- Insight Molecular Diagnostics' Operating Margin (Quarter) stood at 994.15% in 2021, then tumbled by -328bps to 4251.09% in 2022, then dropped by -21bps to 5152.55% in 2023, then soared by 56bps to 2262.92% in 2024, then plummeted by -88bps to 4249.23% in 2025.
- Its last three reported values are 4249.23% in Q3 2025, 1900.0% for Q2 2025, and 318.01% during Q1 2025.